2007
DOI: 10.1007/s00296-006-0289-y
|View full text |Cite
|
Sign up to set email alerts
|

Beneficial effect of treatment with cyclosporin A in a case of refractory antisynthetase syndrome

Abstract: We report a case of idiopathic inflammatory myopathy accompanied with the presence of anti-Jo1 antibodies and complicated by diffuse parenchymal lung disease (antisynthetase syndrome). Efficacy of different therapeutic agents, including corticosteroids, cyclophosphamide and cyclosporin A, is described. We present beneficial effect of cyclosporin A and corticosteroids regimen, and confirm no benefits of plasmapheresis. An interesting association of the disease onset with toxoplasmosis infection is discussed and… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
15
0

Year Published

2009
2009
2024
2024

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 18 publications
(15 citation statements)
references
References 27 publications
0
15
0
Order By: Relevance
“…Less conventional and potential future therapeutic interventions are addressed in Table 6 . [90][91][92][93][94][95][96][97][98][99][100][101][102][103][104] Corticosteroids Empirical treatment of MA-ILD with oral corticosteroids dates to the initial reports of this condition. 3,4 Although the de facto standard of care (historically and currently) for MA-ILD, corticosteroids have little prospective evidence supporting their use.…”
Section: Current Therapeutic Approachesmentioning
confidence: 99%
“…Less conventional and potential future therapeutic interventions are addressed in Table 6 . [90][91][92][93][94][95][96][97][98][99][100][101][102][103][104] Corticosteroids Empirical treatment of MA-ILD with oral corticosteroids dates to the initial reports of this condition. 3,4 Although the de facto standard of care (historically and currently) for MA-ILD, corticosteroids have little prospective evidence supporting their use.…”
Section: Current Therapeutic Approachesmentioning
confidence: 99%
“…There is no consensus on the most effective steroid-sparing immunosuppressive agent or regimen. Agents that have been used with variable success have included cyclophosphamide [38,51], azathioprine [38,43], mycophenolate mofetil [52], cyclosporine [53], tacrolimus [40,54], intravenous immunoglobulin [55], and rituximab [56,57].…”
Section: Treatmentmentioning
confidence: 99%
“…10 Steroid-sparing immunosuppressant agents, including azathioprine, mycophenolate mofetil, cyclosporine, and tacrolimus can be used; however, only case reports are available on the use of these treatments for AS syndrome, and their effects on AS syndrome–associated myocarditis are unknown. 10,5456 Rituximab may be useful, based on a randomized controlled study of patients with DM or PM showing an 83% rate of clinical improvement in those treated with rituximab. 57 The role for B-cell–depleting therapy is further supported in a recent case series of 6 patients with IIMs (3 with PM and 3 with AS syndrome), in which 5 out of 6 patients demonstrated significant improvement with 6 months of rituximab therapy.…”
Section: Discussionmentioning
confidence: 99%